Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONVAX-01 Combination Therapy in Advanced Pancreatic Cancer
NCT07637786Phase 1Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Jun 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in pancreatic adenocarcinoma (PDAC), sponsored by Sichuan University. Primary endpoint: Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) at 36 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07637786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07637786.